Changchun Heber Biological Technology

Changchun Heber Biological Technology is a prominent high-tech joint venture established between the Center for Genetic Engineering and Biotechnology (CIGB) of Cuba and the Changchun Institute of Biological Products of China. The company specializes in the research, development, and large-scale manufacturing of recombinant DNA products, most notably interferon-based therapeutics. Its flagship product, Recombinant Human Interferon alpha 2b (Heberon Alfa R), is widely used in China for the treatment of viral infections such as Hepatitis B and C, as well as various oncological indications. During the COVID-19 pandemic, the company's interferon products gained significant international attention as part of treatment protocols in China and abroad.